BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32880279)

  • 1. Hepatitis C infection at a tertiary hospital in South Africa: Clinical presentation, non-invasive assessment of liver fibrosis, and response to therapy.
    Abuelhassan WB; Gasim GI; Ally R; Menezes C
    S Afr Med J; 2020 Aug; 110(9):920-925. PubMed ID: 32880279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
    Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
    Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection.
    Yosry A; Fouad R; Alem SA; Elsharkawy A; El-Sayed M; Asem N; Hassan E; Ismail A; Esmat G
    Arab J Gastroenterol; 2016 Jun; 17(2):78-83. PubMed ID: 27353055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
    Faisal N; Mumtaz K; Marquez M; Renner EL; Lilly LB
    Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C Viral Kinetic Changes in a Retrospective Cohort Study of Chronic Hepatitis C Virus Egyptian Patients on Pegylated Interferon and Ribavirin Therapy.
    Esmat GE; Al Akel W; Abdel Aziz RA; Al Sayed Taha A; Sabry D; Rashed LA; Mostafa A; El Kazaz AY; Ahmed SH
    J Interferon Cytokine Res; 2016 Mar; 36(3):149-58. PubMed ID: 26982165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
    Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
    Tachi Y; Hirai T; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H
    J Gastroenterol Hepatol; 2016 May; 31(5):1001-8. PubMed ID: 27123974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study.
    Köksal İ; Yılmaz G; Parlak M; Demirdal T; Kınıklı S; Candan M; Kaya A; Akhan S; Aydoğdu Ö; Turgut H; Gürbüz Y; Dağlı Ö; Gökal AA; Güner R; Kuruüzüm Z; Tarakçı H; Beslen N; Erdoğan S; Özdener F; Study Group TCHC
    Turk J Gastroenterol; 2018 Jul; 29(4):464-472. PubMed ID: 30249562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APRI as a predictor of early viral response in chronic hepatitis C patients.
    Mata-Marín JA; Fuentes-Allen JL; Gaytán-Martínez J; Manjarrez-Téllez B; Chaparro-Sánchez A; Arroyo-Anduiza CI
    World J Gastroenterol; 2009 Oct; 15(39):4923-7. PubMed ID: 19842223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to treatment with interferon-alpha and ribavirin in patients with chronic Hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis.
    Parise ER; de Oliveira AC; Conceição RD; Amaral AC; Leite K
    Braz J Infect Dis; 2006 Apr; 10(2):78-81. PubMed ID: 16878256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
    Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic fibrosis and serum alpha-fetoprotein (AFP) as predictors of response to HCV treatment and factors associated with serum AFP normalisation after treatment.
    El Raziky M; Attia D; El Akel W; Shaker O; Khatab H; Abdo S; Elsharkawy A; Esmat G
    Arab J Gastroenterol; 2013 Sep; 14(3):94-8. PubMed ID: 24206736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation and comparison of simple noninvasive models for the prediction of liver fibrosis in chronic hepatitis C.
    Amorim TG; Staub GJ; Lazzarotto C; Silva AP; Manes J; Ferronato Mda G; Shiozawa MB; Narciso-Schiavon JL; Dantas-Correa EB; Schiavon Lde L
    Ann Hepatol; 2012; 11(6):855-61. PubMed ID: 23109448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
    Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
    Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained virological response according to the type of early virological response in HCV and HCV/HIV.
    Lerias de Almeida PR; Alves de Mattos A; Valle Tovo C
    Ann Hepatol; 2010; 9(2):150-5. PubMed ID: 20526007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrosis index based on four factors better predicts advanced fibrosis or cirrhosis than aspartate aminotransferase/platelet ratio index in chronic hepatitis C patients.
    Wang CC; Liu CH; Lin CL; Wang PC; Tseng TC; Lin HH; Kao JH
    J Formos Med Assoc; 2015 Oct; 114(10):923-8. PubMed ID: 26279173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mean Platelet Volume, Red Cell Distribution Width to Platelet Count Ratio, Globulin Platelet Index, and 16 Other Indirect Noninvasive Fibrosis Scores: How Much Do Routine Blood Tests Tell About Liver Fibrosis in Chronic Hepatitis C?
    Thandassery RB; Al Kaabi S; Soofi ME; Mohiuddin SA; John AK; Al Mohannadi M; Al Ejji K; Yakoob R; Derbala MF; Wani H; Sharma M; Al Dweik N; Butt MT; Kamel YM; Sultan K; Pasic F; Singh R
    J Clin Gastroenterol; 2016 Jul; 50(6):518-23. PubMed ID: 26974762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real life application of FIB-4 & APRI during mass treatment of HCV genotype 4 with directly acting anti-viral agents in Egyptian patients, an observational study.
    Said M; Soliman Z; Daebes H; M El-Nahaas S; El-Serafy M
    Expert Rev Gastroenterol Hepatol; 2019 Dec; 13(12):1189-1195. PubMed ID: 31702417
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.